Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Clinicoeconomics and Outcomes Research : CEOR|November 10, 2025
A Method for Adjusting EQ-5D-3L Health State Utilities for Cross-Country Use: Application of a Novel US-to-UK Utility Mapping ApproachAbdul Jabbar Omar Alsaleh, Jerome Msihid, Elisheva Lew, et al.
Diabetes, Obesity & Metabolism|November 25, 2020
How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?Dídac Mauricio, Jukka Westerbacka, Charlie Nicholls, et al.
Diabetes, Obesity & Metabolism|May 2, 2022
Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G studyTimothy S Bailey, Jasvinder Gill, Merwyn Jones S, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|March 12, 2024
An exploratory analysis of the cost-effectiveness of insulin glargine 300 units/mL versus insulin glargine 100 units/mL over a lifetime horizon using the BRAVO diabetes modelHui Shao, Lizheng Shi, Vivian Fonseca, et al.
Endocrinology, Diabetes & Metabolism|July 12, 2019
Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real-world settingFang L Zhou, Charlie Nicholls, Lin Xie, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|April 10, 2023
Cost-effectiveness analysis of once-daily insulin glargine 300 U/mL versus insulin degludec 100 U/mL using the BRAVO diabetes modelHui Shao, Lizheng Shi, Vivian Fonseca, et al.
Advances in Therapy|July 19, 2020
Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World StudyJavier Escalada, Fabrice Bonnet, Jasmanda Wu, et al.
Diabetes, Obesity & Metabolism|September 2, 2022
Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trialWilliam H Polonsky, Francesco Giorgino, Julio Rosenstock, et al.
BMJ Open Diabetes Research & Care|May 29, 2025
Healthcare utilization and costs in adults with type 2 diabetes treated with first or second-generation basal insulins in EnglandNeil Holden, Onyinye Diribe, Karen Palmer, et al.
Blood Advances|August 28, 2025
Efficacy and Safety of Belumosudil as Compared with Best Available Therapy for the Treatment of cGVHD in the USKevin Hall, Aleksandr Lazaryan, Mark van Der Laan, et al.
Pageof 2